Cargando…

Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous leukemia cell lines

BACKGROUND: Chemoresistance remains a significant challenge in chronic myelogenous leukemia (CML) management, which is one of the most critical prognostic factors. Elucidation the molecular mechanisms underlying the resistance to chemoresistance may lead to better clinical outcomes. RESULTS: In orde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qinghong, Shi, Shen, Gao, Lina, Song, Yueming, Zhao, Xiaoou, Li, Jianlin, Wu, Chengyan, He, Hongjun, Li, Haifeng, Zhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307195/ https://www.ncbi.nlm.nih.gov/pubmed/25628518 http://dx.doi.org/10.1186/s12953-014-0057-y

Ejemplares similares

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression
Publicado: (1988)

Minimally differentiated acute myelogenous leukemia presented with multiple cervical lymphadenopathy.
por: Choi, J. H., et al.
Publicado: (1996)

The microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia
por: Wang, Xiao-Shuang, et al.
Publicado: (2008)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
por: Ahmad, Rita, et al.
Publicado: (2021)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
por: Li, Jie, et al.
Publicado: (2019)

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B
por: Yu, Tian, et al.
Publicado: (2023)

miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1
por: Li, An, et al.
Publicado: (2019)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
por: Liesveld, Jane
Publicado: (2012)

Acute Myelogenous Leukemia Mimicking Fulminant Periorbital Cellulitis
por: Bagheri, Abbas, et al.
Publicado: (2013)

Primary hyperparathyroidism in a case of chronic myelogenous leukemia
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Familial Adenomatous Polyposis Complicated by Acute Myelogenous Leukemia
por: Alkofahi, Ala A, et al.
Publicado: (2020)

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia
por: Hu, Tingting, et al.
Publicado: (2022)

Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR
por: Wang, Yu Jia, et al.
Publicado: (2017)

Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic Differentiation in Chronic Myelogenous Leukemia K562 Cells
por: Huang, Huey-Lan, et al.
Publicado: (2011)

Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia
Publicado: (1978)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells
por: Ji, Qing, et al.
Publicado: (2016)

Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
por: Kim, Peter S., et al.
Publicado: (2008)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Spinal epidural granulocytic sarcoma preceding acute myelogenous leukemia.
por: Kook, H., et al.
Publicado: (1992)

Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation()
por: Tsukamoto, Shokichi, et al.
Publicado: (2013)

How mRNA is misspliced in acute myelogenous leukemia (AML)?
por: Mohamed, Aminetou Mint, et al.
Publicado: (2014)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_icc991i2qmskbdi1u0rnihrb1c